Cash and cash equivalents as of December 31, 2023, was $9.2 million as compared to $21.0 million on December 31, 2022. During the first quarter of 2024, Perspective raised aggregate gross proceeds of $20.8 million in a January 2024 private placement, $69.0 million in a January 2024 public offering, and $87.4 million in a March 2024 private placement before deducting underwriting fees, placement agent fees, and other expenses. We believe that our cash and cash equivalents as of December 31, 2023 and the cash we raised through the January 2024 private placement and public offering and the March 2024 private placement will be sufficient to fund our operations and capital investments into 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics to host analyst day
- Perspective Therapeutics announces collaboration agreement with Bristol Myers
- 5 Stocks Corporate Insiders are Buying in March 2024
- Fly Insider : Echostar, Dell among week’s notable insider trades
- Perspective Therapeutics acquires CGMP-compliant manufacturing facility